Abbott Laboratories Intrinsic Value Calculator – Comparing AbbVie and Abbott Laboratories: Which is the Better Growth Stock?
December 22, 2023
☀️Trending News
The company is a leader in the development of medical products and technologies, spanning diagnostics, nutrition, medical devices, generic pharmaceuticals, branded pharmaceuticals, and more. Comparing AbbVie to Abbott Laboratories ($NYSE:ABT) can be a difficult task as both companies are leaders in their respective industries. AbbVie is a biopharmaceutical company focused primarily on developing treatments for autoimmune and immunological conditions. On the other hand, Abbott Laboratories remains committed to its core mission of providing quality healthcare products and services to customers around the world. When it comes to investing in a growth stock, both AbbVie and Abbott Laboratories offer promising opportunities.
However, it is important to evaluate each company’s financials and future prospects in order to make an informed decision. AbbVie has seen tremendous success over the past several years because of its focus on developing innovative treatments for a range of medical conditions. On the other hand, Abbott Laboratories has remained committed to its core mission of providing quality healthcare products and services to customers around the world. Both companies offer promising opportunities for investors seeking long-term growth potential, making it difficult for investors to decide between the two stocks.
Market Price
On Thursday, its stock opened at $107.4 and closed at $108.5, up by 1.0%, which is a great sign for investors looking for long-term growth stocks. In terms of fundamentals, Abbott Laboratories has the upper hand with its strong balance sheet and solid cash flow. Overall, investors looking for a better growth stock should consider investing in Abbott Laboratories rather than AbbVie. With its superior performance and stronger balance sheet, Abbott Laboratories can provide investors with a solid return on their investment over the long term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 39.96k | 5.16k | 12.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 7.45k | -1.74k | -7.64k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 73.35k | 35.95k | 21.42 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.4% | 11.6% | 16.3% |
| FCF Margin | ROE | ROA |
| 13.7% | 11.0% | 5.6% |
Analysis – Abbott Laboratories Intrinsic Value Calculator
At GoodWhale, we have conducted a thorough analysis of ABBOTT LABORATORIES‘s fundamentals, and our findings are encouraging. We are confident that the company has a strong financial position with a high intrinsic value of $124.1. This value was determined by our proprietary Valuation Line system, which looks at a range of factors such as revenue, profitability, debt-to-equity ratio and current market prices. As it stands, ABBOTT LABORATORIES’s share price is currently trading at $108.5, which is a fair price considering that this is 12.6% lower than the estimated intrinsic value. As such, we believe that investing in ABBOTT LABORATORIES would be a smart move for those looking to add a strong stock to their portfolio. More…
Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
Abbott Laboratories is a diversified healthcare company with a long-term track record of financial stability. It focuses on developing and manufacturing innovative products and services, ranging from medical devices, pharmaceuticals, nutrition products and diagnostics. Investing in Abbott Laboratories can offer investors a reliable and relatively low-risk growth stock with a strong dividend. The company has a history of consistently delivering strong earnings and dividend growth, as well as a solid balance sheet.
Abbott Labs has also been increasing its presence in fast-growing markets such as China and India, leading to further potential growth in the long term. The company’s low debt/equity ratio provides financial flexibility to invest in new products, technologies, and markets.
